Inhibikase Therapeutics, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing protein kinase inhibitors for Parkinson’s disease, Parkinson’s-related disorders, other Abelson Tyrosine Kinase diseases, and certain oncology applications. The lead program is risvodetinib (IkT-148009), including the Phase 2 Parkinson’s disease “201 trial.” The company also develops IkT-001Pro, a prodrug of imatinib mesylate. The filing covers the three months ended March 31, 2024, with unaudited financial statements.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $64,521 | Down 100.0% |
| Research and development expense | $2.75 million | $2.85 million | Down 3.6% |
| SG&A expense | $2.03 million | $1.93 million | Up 5.5% |
| Loss from operations | $4.78 million | $4.71 million | Loss increased 1.4% |
| Net loss | $4.65 million | $4.48 million | Loss increased 3.8% |
| Net loss per share | $0.73 | $0.98 | Loss per share improved due primarily to higher share count |
| Net cash used in operating activities | $3.87 million | $5.97 million | Use decreased $2.11 million |
Revenue consisted solely of grant revenue in the prior-year period; the company has not generated revenue from commercial product sales. A meaningful revenue or operating margin percentage is not applicable because Q1 2024 revenue was zero.
At March 31, 2024, cash and cash equivalents were $2.35 million, marketable securities were $7.40 million, and working capital was $6.57 million. Total assets were $11.07 million and total liabilities were $4.29 million. The company reported an accumulated deficit of $71.55 million.
The company has no reported conventional debt. Obligations include $209,489 of operating lease liabilities, $280,614 of insurance premium financing payable, and other current liabilities. The Lexington office lease runs through September 30, 2025, with remaining minimum payments of $227,803 as of March 31, 2024.
Investing activities used $3.31 million, reflecting $8.43 million of purchases of marketable securities partially offset by $5.12 million of maturities. Financing activities provided $367,000, including $397,607 of net proceeds from the company’s ATM offering, partially offset by deferred offering costs.
Material changes versus the prior comparable period
- Grant revenue fell from $64,521 to zero because current clinical trial activities were not submitted for grant revenue.
- R&D expense declined $102,840. Parkinson’s disease spending increased $586,449, while IkT-001Pro spending decreased $737,826 and MSA spending decreased $31,948.
- SG&A increased $105,730, primarily because legal and consulting fees increased by approximately $180,000.
- Interest income declined $104,446 to $132,725, reflecting lower balances invested in U.S. Treasuries and money market instruments.
- Common shares outstanding increased to 6,476,844 at March 31, 2024 from 6,186,280 at December 31, 2023. The increase primarily reflected 290,564 shares sold under the ATM program.
- Net cash used in operations improved year over year, but the company’s cash and cash equivalents declined by $6.81 million during the quarter because of operating losses and net purchases of marketable securities.
Guidance, outlook, risks, contingencies, and unusual items
Management estimates that available working capital, including funds raised through the February 2024 ATM offering, will fund normal operations through November 2024. The filing states that substantial doubt exists regarding the company’s ability to continue as a going concern for one year after issuance of the financial statements. Management expects to seek additional equity, debt, grant, licensing, or collaboration funding and may suspend or delay research programs and capital expenditures or reduce operating expenses if funding is unavailable.
The company may sell up to approximately $5.7 million of common stock under the ATM agreement; $397,607 of net proceeds had been received through March 31, 2024. Further equity financing could dilute existing stockholders, while debt financing could increase fixed obligations and impose restrictive covenants.
As of May 10, 2024, the 201 trial had 99 enrolled participants, 32 active sites, 44 participants who had completed the 12-week dosing period, and 15 prospective participants in medical screening. Management indicated that trial results may be reported in the second half of 2024 and is considering extending the study by up to 12 months, subject to additional resources. Reported potentially treatment-related adverse events included 25 mild and three moderate events across enrolled patients.
Risvodetinib received FDA Orphan Drug Designation for multiple system atrophy. The company plans a potential Phase 2 MSA study but is seeking non-dilutive funding before initiating it. For IkT-001Pro, the FDA indicated that the 505(b)(2) pathway appears appropriate, subject to formal review of clinical data, and requested additional dose, absorption, safety, manufacturing, and medication-error evaluations.
On April 26, 2024, after the quarter end, Pivot Holding LLC demanded arbitration alleging breach of a 2012 research and development agreement and seeking $1.625 million of milestone payments plus interest. The company disputes the claims and intends to defend them; mediation was agreed before arbitration, and the company’s response was due June 17, 2024.
Key risks include continued operating losses, lack of approved commercial products, clinical and regulatory uncertainty, possible future clinical holds, dependence on third-party manufacturers and research providers, the need for additional capital, potential dilution, intellectual-property risks, and adverse clinical trial outcomes. The company stated that FDA clinical holds relating to the risvodetinib Parkinson’s disease and MSA programs had been lifted.
Important facts for investors to verify
- Whether the company completes additional financing before its estimated November 2024 liquidity horizon and on what terms.
- Enrollment progress, safety data, timing, and results for the 201 Parkinson’s disease trial and any decision to extend it.
- Regulatory requirements, clinical plans, and financing for risvodetinib’s MSA program.
- FDA feedback and additional studies required for IkT-001Pro, including the 505(b)(2) pathway and potential PAH program.
- The status and potential financial exposure of the Pivot arbitration claim.
- The remaining capacity and future share dilution under the $5.7 million ATM program.
- Whether cash, marketable securities, and anticipated funding are sufficient to maintain planned clinical development and support going-concern viability.